Conclusion
AIED is one of the few forms of SNHL for which a treatment is available
therefore early diagnosis and intervention is important. We report a
case of secondary AIED in patient with a significant response to
infliximab therapy. Studies on the use of anti-TNFα therapy for AIED as
a steroid-sparing alternative are limited and showed variable results.
To assess and establish the efficacy of anti-TNFα therapy in the
management of AIED, large multicentre randomised controlled trials are
required that measure not only improvement in hearing but also other
aural symptoms. This, however, may be difficult due to the rarity of the
condition and the lack of a standardised diagnostic criteria.